Page last updated: 2024-12-04

benzphetamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Benzphetamine: A sympathomimetic agent with properties similar to DEXTROAMPHETAMINE. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

benzphetamine : Dextroamphetamine in which the the hydrogens attached to the amino group are substituted by a methyl and a benzyl group. A sympathomimetic agent with properties similar to dextroamphetamine, it is used as its hydrochloride salt in the treatment of obesity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5311017
CHEMBL ID3545985
CHEBI ID3044
SCHEMBL ID49120
MeSH IDM0002381

Synonyms (62)

Synonym
CHEBI:3044 ,
benzfetaminum
benzfetamina
(2s)-n-benzyl-n-methyl-1-phenylpropan-2-amine
benzeneethanamine, n,alpha-dimethyl-n-(phenylmethyl)-, (s)-
n,alpha-dimethyl-n-(phenylmethyl)-benzeneethanamine
(r,s)-n-benzyl-alpha,n-dimethylphenethylamin
hsdb 3294
n-benzylmethamphetamin
benzfetaminum [latin]
brn 3203999
benzfetamine [inn:ban]
phenethylamine, n-benzyl-n,alpha-dimethyl-, (+)-
benzfetamina [inn-spanish]
benzfetamina [dcit]
benzphetaminum [inn-latin]
benzfetaminum [inn-latin]
benzofetamina [inn-spanish]
d-benzphetamine
benzfetamina [spanish]
benzeneethanamine, n,alpha-dimethyl-n-(phenylmethyl)-, (+)-
benzfetamine
156-08-1
benzphetamine
DB00865
(alphas)-n,alpha-dimethylphenethylamine
n-methyl-1-phenyl-n-(phenylmethyl)propan-2-amine
benzaphetamine
(+)-n,alpha-dimethyl-n-(phenylmethyl)-benzeneethanamine
d-n-methyl-n-benzyl-beta-phenylisopropylamine
(+)-benzphetamine
(s)-(+)-n-benzyl-n,alpha-dimethylphenethylamine
(+)-n-benzyl-n,alpha-dimethylphenethylamine
(s)-(+)-benzphetamine
(s)-benzphetamine
unii-0m3s43xk27
benzphetaminum
benzofetamina
n-benzylmethamphetamine
0m3s43xk27 ,
benzphetamine [vandf]
benzfetamine [inn]
benzphetamine [hsdb]
(+)-n-benzyl-n,.alpha.-dimethylphenethylamine
benzeneethanamine, n,.alpha.-dimethyl-n-(phenylmethyl)-, (.alpha.s)-
benzfetamine [who-dd]
benzphetamine [mi]
SCHEMBL49120
CHEMBL3545985
DTXSID4022656 ,
benzyl(methyl)[(2s)-1-phenylpropan-2-yl]amine
(s)-n-benzyl-n-methyl-1-phenylpropan-2-amine
YXKTVDFXDRQTKV-HNNXBMFYSA-N
156-08-1 (free base)
benzofetamina (inn-spanish)
benzfetaminum (inn-latin)
benzeneethanamine, n,alpha-dimethyl-n-(phenylmethyl)-, (alphas)-
(alphas)-n,alpha-dimethyl-n-(phenylmethyl)benzeneethanamine
benzfetaminum (latin)
benzfetamina (inn-spanish)
benzphetaminum (inn-latin)
dtxcid302656

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Parallel pharmacokinetic studies in the same monkeys determined plasma benzphetamine, d-methamphetamine and/or d-amphetamine levels for correlation with behavioral effects."( Role of d-amphetamine and d-methamphetamine as active metabolites of benzphetamine: Evidence from drug discrimination and pharmacokinetic studies in male rhesus monkeys.
Banks, ML; Fennell, TR; Negus, SS; Snyder, RW, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
"The intestinal mucosa plays a capital role in dictating the bioavailability of a large array of orally ingested drugs and toxicants."( Characterization of xenobiotic metabolizing enzymes in bovine small intestinal mucosa.
Cantiello, M; Carletti, M; Della Donna, L; Gardini, G; Girolami, F; Nebbia, C; Virkel, G, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Furthermore, usual increase in the activity of drug biotransformation enzymes seen after phenobarbital treatment appears to decrease in rats dosed with this funaicide."( Toxicologic studies of N-trichloromethylthio-4-cyclohexene-1,2-dicarboximide (captan): its metabolism by rat liver drug-metabolizing enzyme system.
Dalvi, RR; Peeples, A, 1978
)
0.26
"Pretreatment of rats with a dosage regimen of alphaMT that has no effect on the anorectic action of a single dose of 2 mg/kg of d-amphetamine or methamphetamine causes a marked reduction in the rate of continuous avoidance responding evoked by that same dose."( Differential effects of alphaMT on anorectic and stimulatory action of amphetamines.
Cox, RH; Maickel, RP, 1975
)
0.25
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
sympathomimetic agentA drug that mimics the effects of stimulating postganglionic adrenergic sympathetic nerves. Included in this class are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.
dopamine uptake inhibitorA dopaminergic agent that blocks the transport of dopamine into axon terminals or into storage vesicles within terminals. Most of the adrenergic uptake inhibitors also inhibit dopamine uptake.
appetite depressantAgent that is used to decrease appetite.
adrenergic uptake inhibitorAdrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tertiary amineA compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.
amphetaminesAmines that constitute a class of central nervous system stimulants based on the structure of the parent amphetamine 1-phenylpropan-2-amine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (297)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990205 (69.02)18.7374
1990's47 (15.82)18.2507
2000's35 (11.78)29.6817
2010's10 (3.37)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.61%)5.53%
Reviews7 (2.13%)6.00%
Case Studies1 (0.30%)4.05%
Observational0 (0.00%)0.25%
Other319 (96.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]